R-Cinex EZ (Isoniazid/Rifampicin/Ethambutol/Pyrazinamide)

R-Cinex EZ (Isoniazid/Rifampicin/Ethambutol/Pyrazinamide)

R-Cinex EZ is a fixed-dose combination medication used in the treatment of tuberculosis (TB), especially effective in the initial intensive phase of therapy. It contains four first-line anti-TB drugs: Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide—each with a distinct mechanism of action that targets Mycobacterium tuberculosis, the bacteria responsible for TB.

• Isoniazid inhibits the synthesis of mycolic acid in the bacterial cell wall.

• Rifampicin interferes with RNA synthesis.

• Ethambutol impairs cell wall formation.

• Pyrazinamide works well in acidic environments like within infected cells, targeting dormant bacteria.

This powerful combination ensures rapid bacterial kill, reduces the risk of resistance, and improves patient compliance by minimizing pill burden. R-Cinex EZ is typically prescribed under DOTS (Directly Observed Treatment, Short-course) as part of a national TB control program.

Possible side effects include liver enzyme elevation, gastrointestinal discomfort, red/orange discoloration of bodily fluids (from Rifampicin), or visual disturbances (from Ethambutol). Regular monitoring is essential during therapy.